RxDoctor Payments Data

Nosa Aigbe Lebarty, MD

Hospitalist · Schenectady, NYNPI 1629385315

Payments from drug & device makers

$554in general payments, 2019–2025

Across 24 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$128
  • AbbVie$62
  • Novo Nordisk$57
  • Pfizer$49
  • AstraZeneca$43
  • Orexo US, Inc.$42
  • plus $173 from 6 others

What the payments were for

  • Food & beverage$48888%
  • Education$6612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$554 in reported general payments places this provider in the 80th percentile of 1,860 hospitalist providers in New York.

See all hospitalist providers in New York

Medicare billing

Part B allowed, 2024
$21,849
Medicare patients
95
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban530$141,578
XeljanzTofacitinib Citrate11$67,832
Invega SustennaPaliperidone Palmitate15$53,795
JardianceEmpagliflozin78$22,717
JanuviaSitagliptin Phosphate68$19,317
XifaxanRifaximin14$19,258
TradjentaLinagliptin67$19,153
EntrestoSacubitril/Valsartan57$18,266
TrulicityDulaglutide22$17,489
CreonLipase/Protease/Amylase17$17,246
FarxigaDapagliflozin Propanediol55$16,380
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,229
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog79$11,492
FiaspInsulin Aspart (Niacinamide)34$10,612
ArexvyRsvpref3 Antigen/As01e/Pf34$10,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Xeljanz$49$209,410541 claims
Johnson & JohnsonInvega Sustenna, Xarelto$27$59,46538 claims
Boehringer IngelheimJardiance, Tradjenta$24$41,870145 claims
AstraZenecaFarxiga, Brilinta, Bevespi Aerosphere$43$27,35894 claims
AbbVieCreon$62$17,24617 claims
Novo NordiskFiasp$57$10,61234 claims
Astellas Pharma US IncMyrbetriq$128$6,70929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,860 hospitalist providers in New York.

Other hospitalist in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →